The global plasma fractionation market valued USD 28,605 million in 2022, from where it is set to reach USD 50,638 million by 2030, at a 7.4% CAGR between 2022 and 2030. The increasing funding and corporate involvement in research & development activities for plasma treatment and the rising awareness of blood donation are projected to create profitable revenue opportunities for the industry players.
Moreover, the market is growing with the frequent respiratory disease outbreaks, an aging population with blood-related illnesses, and rising immunoglobulin consumption. The surge in the incidence of rare diseases that require plasma therapy or plasma derivatives is another major factor behind the market's expansion.
The increase in the incidence of various immunodeficiency illnesses around the world is resulting in a significant rise in the demand for plasma-derived medicines. The strong growth in the immunoglobulin demand has essentially resulted in market expansion on a global scale.
The hospitals & clinics category accounted for the largest revenue share, of around 50%, in 2022, and it is further expected to maintain its position during the forecast period. Because plasma products are being used more frequently to treat a variety of immunological, neurological, and bleeding disorders, more hospitals and clinics are opening around the world. Moreover, due to the large pool of patients that visits them, these healthcare organizations are working with plasma product manufacturers to ensure a consistent supply of therapies.
The clinical research laboratories category comes in second. This is a result of the expanding R&D initiatives to create more plasma-derived medicinal products for a number of uncommon diseases.
Based on product type, the coagulation factors category is projected to show the fastest growth during the forecast period, due to the launch of a wide range of products that can assist physicians in providing proper care to patients with hemophilia. In this regard, the category’s growth is fueled by an increase in the count of road accidents and trauma cases. The death rate in patients of severe physical trauma with clotting disorders is 3–4 times higher than among individuals without coagulation issues.
Geographically, the APAC region is expected to emerge as the fastest-growing market, driven by the advancement of the healthcare infrastructure, expansion of research outcomes, increase in the usage of immunoglobulins, and rise in the prevalence of target diseases, with an aging population. Additionally, the regional market is expanding with the swift medical tourism and economic growth, especially in China and India, which also house a huge number of patients. Moreover, the rising demand for plasma-based treatments among people with blood-related problems is a key factor for the market expansion in the region.
Moreover, Australia will show significant growth in this market in APAC due to an increase in the public and private funding for research & development, favorable government regulations, adoption of immunoglobulins and other plasma derivatives for the treatment of blood disorders, and rising prevalence of chronic diseases in the geriatric population.
Moreover, Latin America and the Middle East & Africa are expected to show significant plasma fractionation market growth in the forecast period, primarily due to the increasing prevalence of autoimmune diseases.
Some of the major market players are Japan Blood Products Organization, CSL Behring, GC Biopharma, Octapharma AG, Bio Product Laboratory Ltd., Grifols International, S.A., Kedrion S.p.A., Takeda Pharmaceutical Company Limited, and Intas Pharmaceuticals Ltd.